Alzheimer's Disease Research Today is a free monthly online journal that collates and summarizes the latest research about Alzheimer's Disease, including details on diagnosis, memory loss, heredity, treatment, medication.

Volume 2 (2005), Issue 4 (April)

1. Abnormal spatial and non-spatial cueing effects in mild cognitive impairment and Alzheimer's disease.
   Neurocase, 11(1): 85-92. [Abstract] [Full-text]
2. Abnormal visual search in mild cognitive impairment and Alzheimer's disease.
   Neurocase, 11(1): 80-4. [Abstract] [Full-text]
3. A decade of pre-diagnostic assessment in a case of familial Alzheimer's disease: tracking progression from asymptomatic to MCI and dementia.
   Neurocase, 11(1): 56-64. [Abstract] [Full-text]
4. Years of severe and isolated amnesia can precede the development of dementia in early-onset Alzheimer's disease.
   Neurocase, 11(1): 48-55. [Abstract] [Full-text]
5. Cerebrospinal fluid TAU protein and amyloid beta42 in mild cognitive impairment: prediction of progression to Alzheimer's disease and correlation with the neuropsychological examination.
   Neurocase, 11(1): 32-9. [Abstract] [Full-text]
6. Biomarker profiles and their relation to clinical variables in mild cognitive impairment.
   Neurocase, 11(1): 8-13. [Abstract] [Full-text]
7. The apolipoprotein E epsilon4 allele and incident Alzheimer's disease in persons with mild cognitive impairment.
   Neurocase, 11(1): 3-7. [Abstract] [Full-text]
8. Positive affect among nursing home residents with Alzheimer's dementia: the effect of recreational activity.
   Aging Ment Health, 9(2): 129-34. [Abstract] [Full-text]
9. 1H MR spectroscopy using TE averaged PRESS: a more sensitive technique to detect neurodegeneration associated with Alzheimer's disease.
   Magn Reson Med, 53(4): 777-82. [Abstract] [Full-text]
10. PAR-4 is involved in regulation of beta-secretase cleavage of the Alzheimer amyloid precursor protein.
    J Biol Chem, 280(14): 13824-32. [Abstract] [Full-text]
11. Methylation of the imidazole side chains of the Alzheimer disease amyloid-beta peptide results in abolition of superoxide dismutase-like structures and inhibition of neurotoxicity.
    J Biol Chem, 280(14): 13355-63. [Abstract] [Full-text]
12. Mu-calpain is functionally required for alpha-processing of Alzheimer's beta-amyloid precursor protein.
    Biochem Biophys Res Commun, 330(3): 714-21. [Abstract] [Full-text]
13. Preclinical detection of Alzheimer's disease: hippocampal shape and volume predict dementia onset in the elderly.
    Neuroimage, 25(3): 783-92. [Abstract] [Full-text]
14. Neurovascular mechanisms of Alzheimer's neurodegeneration.
    Trends Neurosci, 28(4): 202-8. [Abstract] [Full-text]
15. A method for detection of Alzheimer's disease using ICA-enhanced EEG measurements.
    Artif Intell Med, 33(3): 209-22. [Abstract] [Full-text]
16. Stereological analysis of microvascular parameters in a double transgenic model of Alzheimer's disease.
    Brain Res Bull, 65(4): 317-22. [Abstract] [Full-text]
17. Working memory impairment in a transgenic amyloid precursor protein TgCRND8 mouse model of Alzheimer's disease.
    Genes Brain Behav, 4(3): 197-208. [Abstract] [Full-text]
18. Behavioral phenotypes of amyloid-based genetically modified mouse models of Alzheimer's disease.
    Genes Brain Behav, 4(3): 173-96. [Abstract] [Full-text]
19. A case for a non-transgenic animal model of Alzheimer's disease.
    Genes Brain Behav, 4(3): 157-72. [Abstract] [Full-text]
20. Invertebrate models of Alzheimer's disease.
    Genes Brain Behav, 4(3): 147-56. [Abstract] [Full-text]
21. Genetic and molecular aspects of Alzheimer's disease shed light on new mechanisms of transcriptional regulation.
    Genes Brain Behav, 4(3): 134-46. [Abstract] [Full-text]
22. The clinical syndrome of Alzheimer's disease: aspects particularly relevant to clinical trials.
    Genes Brain Behav, 4(3): 129-33. [Abstract] [Full-text]
23. Reduced CSF PLTP activity in Alzheimer's disease and other neurologic diseases; PLTP induces ApoE secretion in primary human astrocytes in vitro.
    J Neurosci Res, 80(3): 406-13. [Abstract] [Full-text]
24. Somatostatin regulates brain amyloid beta peptide Abeta42 through modulation of proteolytic degradation.
    Nat Med, 11(4): 434-9. [Abstract] [Full-text]
25. A comparison of donepezil and galantamine in the treatment of cognitive symptoms of Alzheimer's disease: a meta-analysis.
    Hum Psychopharmacol, 20(3): 183-7. [Abstract] [Full-text]
26. "Where to?" remote memory for spatial relations and landmark identity in former taxi drivers with Alzheimer's disease and encephalitis.
    J Cogn Neurosci, 17(3): 446-62. [Abstract] [Full-text]
27. The novel cytosolic RING finger protein dactylidin is up-regulated in brains of patients with Alzheimer's disease.
    Eur J Neurosci, 21(5): 1289-98. [Abstract] [Full-text]
28. Neuronal microtubules: when the MAP is the roadblock.
    Trends Cell Biol, 15(4): 183-7. [Abstract] [Full-text]
29. Stereologic analysis of hippocampal Alzheimer's disease pathology in the oldest-old: evidence for sparing of the entorhinal cortex and CA1 field.
    Exp Neurol, 193(1): 198-206. [Abstract] [Full-text]
30. Allothetic orientation and sequential ordering of places is impaired in early stages of Alzheimer's disease: corresponding results in real space tests and computer tests.
    Behav Brain Res, 159(2): 175-86. [Abstract] [Full-text]
31. A measure of subjective burden for dementia care: the Caregiving Difficulty Scale--Intellectual Disability.
    J Intellect Disabil Res, 49: 365-71. [Abstract] [Full-text]
32. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment.
    J Am Geriatr Soc, 53(4): 695-9. [Abstract] [Full-text]
33. High prevalence of Chlamydia pneumoniae antibodies and increased high-sensitive C-reactive protein in patients with vascular dementia.
    J Am Geriatr Soc, 53(4): 583-9. [Abstract] [Full-text]
34. Diagnosis of Alzheimer's disease using brain perfusion SPECT and MR imaging: which modality achieves better diagnostic accuracy?
    Eur J Nucl Med Mol Imaging, 32(4): 414-21. [Abstract] [Full-text]
35. Decreased serum amyloid beta(1-42) autoantibody levels in Alzheimer's disease, determined by a newly developed immuno-precipitation assay with radiolabeled amyloid beta(1-42) peptide.
    Biol Psychiatry, 57(7): 813-6. [Abstract] [Full-text]
36. Early behavioral symptoms and course of Alzheimer's disease.
    Acta Psychiatr Scand, 111(5): 367-71. [Abstract] [Full-text]
37. Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. FDG-PET studies in MCI and AD.
    Eur J Nucl Med Mol Imaging, 32(4): 486-510. [Abstract] [Full-text]
38. Therapeutic potential of positive AMPA modulators and their relationship to AMPA receptor subunits. A review of preclinical data.
    Psychopharmacology (Berl), 179(1): 154-63. [Abstract] [Full-text]
39. Alzheimer's disease: Abeta, tau and synaptic dysfunction.
    Trends Mol Med, 11(4): 170-6. [Abstract] [Full-text]
40. Tau phosphorylation in Alzheimer's disease: pathogen or protector?
    Trends Mol Med, 11(4): 164-9. [Abstract] [Full-text]
41. Serum or cerebrospinal fluid levels of glyceraldehyde-derived advanced glycation end products (AGEs) may be a promising biomarker for early detection of Alzheimer's disease.
    Med Hypotheses, 64(6): 1205-7. [Abstract] [Full-text]
42. CSF biomarkers for mild cognitive impairment and early Alzheimer's disease.
    Clin Neurol Neurosurg, 107(3): 165-73. [Abstract] [Full-text]
43. Dual specificity protein phosphatases: therapeutic targets for cancer and Alzheimer's disease.
    Annu Rev Pharmacol Toxicol, 45: 725-50. [Abstract] [Full-text]
44. Genetic association analysis: lessons from the study of Alzheimers disease.
    Mutat Res, 573(1): 152-9. [Abstract] [Full-text]
45. Homocysteine and related genetic polymorphisms in Down's syndrome IQ.
    J Neurol Neurosurg Psychiatry, 76(5): 706-9. [Abstract] [Full-text]
46. Rate of progression of cognitive decline in Alzheimer's disease: effect of butyrylcholinesterase K gene variation.
    J Neurol Neurosurg Psychiatry, 76(5): 640-3. [Abstract] [Full-text]
47. Neurogenetics II: complex disorders.
    J Neurol Neurosurg Psychiatry, 76(5): 623-31. [Abstract] [Full-text]
48. Modelling of calcium dynamics in brain energy metabolism and Alzheimer's disease.
    Comput Biol Chem, 29(2): 151-62. [Abstract] [Full-text]
49. Lipid homeostasis and apolipoprotein E in the development and progression of Alzheimer's disease.
    J Lipid Res, 46(5): 949-68. [Abstract] [Full-text]
50. Endogenous oxidative stress in sporadic Alzheimer's disease neuronal cybrids reduces viability by increasing apoptosis through pro-death signaling pathways and is mimicked by oxidant exposure of control cybrids.
    Neurobiol Dis, 19(1): 312-22. [Abstract] [Full-text]
51. Cholinesterase inhibitors influence APP metabolism in Alzheimer disease patients.
    Neurobiol Dis, 19(1): 237-42. [Abstract] [Full-text]
52. Reduced brain tissue perfusion in TGF-beta 1 transgenic mice showing Alzheimer's disease-like cerebrovascular abnormalities.
    Neurobiol Dis, 19(1): 38-46. [Abstract] [Full-text]
53. Investigation of the effect of brain-derived neurotrophic factor (BDNF) polymorphisms on the risk of late-onset Alzheimer's disease (AD) and quantitative measures of AD progression.
    Neurosci Lett, 379(3): 229-34. [Abstract] [Full-text]
54. Association study of the chemokine, CXC motif, ligand 1 (CXCL1) gene with sporadic Alzheimer's disease in a Japanese population.
    Neurosci Lett, 379(3): 149-51. [Abstract] [Full-text]
55. Soluble interleukin-1 receptor type II, IL-18 and caspase-1 in mild cognitive impairment and severe Alzheimer's disease.
    Neurochem Int, 46(7): 551-7. [Abstract] [Full-text]
56. Cognitive, behavioral, and physiological changes in Alzheimer disease patients as a function of incontinence medications.
    Am J Geriatr Psychiatry, 13(4): 324-8. [Abstract] [Full-text]
57. Effects of previous major depressive illness on cognition in Alzheimer disease patients.
    Am J Geriatr Psychiatry, 13(4): 312-8. [Abstract] [Full-text]
58. Regional cortical blood flow changes following sodium lactate infusion in Alzheimer's disease.
    Eur J Neurosci, 21(6): 1671-8. [Abstract] [Full-text]
59. The 9 year cognitive decline before dementia of the Alzheimer type: a prospective population-based study.
    Brain, 128: 1093-101. [Abstract] [Full-text]
60. Application of a non-linear image registration algorithm to quantitative analysis of T2 relaxation time in transgenic mouse models of AD pathology.
    J Neurosci Methods, 144(1): 91-7. [Abstract] [Full-text]
61. Development of an optical approach for noninvasive imaging of Alzheimer's disease pathology.
    J Biomed Opt, 10(1): 11007. [Abstract] [Full-text]
62. Genome screen for loci influencing age at onset and rate of decline in late onset Alzheimer's disease.
    Am J Med Genet B Neuropsychiatr Genet, 135(1): 24-32. [Abstract] [Full-text]
63. Autoantibodies to redox-modified oligomeric Abeta are attenuated in the plasma of Alzheimer's disease patients.
    J Biol Chem, 280(17): 17458-63. [Abstract] [Full-text]
64. Catechol oxidase-like oxidation chemistry of the 1-20 and 1-16 fragments of Alzheimer's disease-related beta-amyloid peptide: their structure-activity correlation and the fate of hydrogen peroxide.
    J Biol Chem, 280(17): 16601-9. [Abstract] [Full-text]
65. Estrogen and cognition, with a focus on Alzheimer's disease.
    Semin Reprod Med, 23(2): 172-9. [Abstract] [Full-text]
66. Alzheimer's disease: channeling APP to non-amyloidogenic processing.
    Biochem Biophys Res Commun, 331(2): 375-8. [Abstract] [Full-text]
67. Activity of flurbiprofen and chemically related anti-inflammatory drugs in models of Alzheimer's disease.
    Brain Res Brain Res Rev, 48(2): 400-8. [Abstract] [Full-text]
68. Transgenic AD model mice, effects of potential anti-AD treatments on inflammation and pathology.
    Brain Res Brain Res Rev, 48(2): 370-8. [Abstract] [Full-text]
69. From proteomics to biomarker discovery in Alzheimer's disease.
    Brain Res Brain Res Rev, 48(2): 360-9. [Abstract] [Full-text]
70. Interactions between Alzheimer's disease and cerebral ischemia--focus on inflammation.
    Brain Res Brain Res Rev, 48(2): 240-50. [Abstract] [Full-text]
71. Post-translational processing of beta-secretase in Alzheimer's disease.
    Proteomics, 5(6): 1533-43. [Abstract] [Full-text]
72. CD14 receptor polymorphism and Alzheimer's disease risk.
    Neurosci Lett, 380(1): 193-6. [Abstract] [Full-text]
73. Differences in magnetization transfer ratios of the hippocampus between dementia with Lewy bodies and Alzheimer's disease.
    Neurosci Lett, 380(1): 166-9. [Abstract] [Full-text]
74. Cognitive correlates of alterations in acetylcholinesterase in Alzheimer's disease.
    Neurosci Lett, 380(1): 127-32. [Abstract] [Full-text]
75. Cognitive performance in Alzheimer's disease patients receiving rivastigmine for up to 5 years.
    Int J Clin Pract, 59(4): 473-7. [Abstract] [Full-text]
76. Collagenous Alzheimer amyloid plaque component assembles amyloid fibrils into protease resistant aggregates.
    FEBS J, 272(9): 2231-6. [Abstract] [Full-text]
77. Increased oxidative damage in nuclear and mitochondrial DNA in Alzheimer's disease.
    J Neurochem, 93(4): 953-62. [Abstract] [Full-text]
78. Inhibitory control of saccadic eye movements and cognitive impairment in Alzheimer's disease.
    Biol Psychiatry, 57(9): 1052-60. [Abstract] [Full-text]
79. Progestins and estrogens and Alzheimer's disease.
    J Steroid Biochem Mol Biol, 93(2): 305-8. [Abstract] [Full-text]

© 2004-2008 Alzheimer's Disease Research Today. All Rights Reserved.